Profound Medical Corp.
PROF
$6.15
$0.152.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 91.59% | -- | -- | -- | 8.91% |
| Total Other Revenue | 25.16% | 31.66% | 53.53% | -8.86% | -1.91% |
| Total Revenue | 82.14% | 84.42% | 63.89% | 39.39% | -22.63% |
| Cost of Revenue | 34.03% | 15.78% | 53.59% | 44.02% | -13.83% |
| Gross Profit | 113.97% | 155.21% | 70.38% | 36.95% | -27.53% |
| SG&A Expenses | 71.13% | 13.92% | 57.91% | 17.25% | 14.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 47.99% | 15.13% | 42.62% | 25.23% | 6.99% |
| Operating Income | -41.75% | 0.66% | -37.01% | -21.71% | -15.04% |
| Income Before Tax | -63.22% | 37.34% | -65.65% | 5.75% | 3.91% |
| Income Tax Expenses | 2.50% | -3.93% | 883.33% | -42.86% | -16.67% |
| Earnings from Continuing Operations | -62.85% | 38.43% | -68.30% | 5.93% | 3.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.85% | 38.43% | -68.30% | 5.93% | 3.99% |
| EBIT | -41.75% | 0.66% | -37.01% | -21.71% | -15.04% |
| EBITDA | -44.26% | 2.18% | -39.36% | -23.03% | -15.25% |
| EPS Basic | -31.73% | 48.94% | -45.97% | 18.53% | 17.33% |
| Normalized Basic EPS | -32.01% | 48.06% | -43.65% | 18.41% | 17.25% |
| EPS Diluted | -31.73% | 49.30% | -45.97% | 18.53% | 17.33% |
| Normalized Diluted EPS | -32.01% | 48.06% | -43.65% | 18.41% | 17.25% |
| Average Basic Shares Outstanding | 23.65% | 20.60% | 15.32% | 15.48% | 16.12% |
| Average Diluted Shares Outstanding | 23.65% | 20.60% | 15.32% | 15.48% | 16.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |